## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Hans-Peter BUCHSTALLER et al.

Confirmation No.

ATTORNEY DOCKET NO. 24945-0026US

Applic. No.: 10/564,185

Art Unit: Unassigned

Filed: January 11, 2006

Examiner: Unassigned

For:

BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a prima facie prior art reference against the claims of the present application.

## **RELEVANCE STATEMENT**

The foregoing documents came to the Applicant's attention during a search of the corresponding international application. A copy of the International Search Report forth the portion of each reference considered relevant by the examiner is attached.

## TIMING/FEES

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Patricia & Grando

Date: april 24, 2006

Heller Ehrman LLP

1717 Rhode Island Avenue, NW Washington, D.C. 20036

Telephone: (202) 912-2000

Facsimile:

(202) 912-2020

Patricia D. Granados Attorney for Applicant

Reg. No.: 33,683

Customer No. 26633

Approved for use through 10/31/2002. OMB 0651-0031

Unassigned 24945-0026US

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number 10/564,185

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Filing Date January 11, 2006

First Named Inventor Hans-Peter BUCHSTALLER et al.

Group Art Unit Unassigned

Attorney Docket Number

**Examiner Name** 

U.S. PATENT DOCUMENTS								
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear			
Initials *		Number - Kind Code <sup>2</sup> (if known)						
	A01	4,002,623	1/11/1977	Kadin				
	A02	4,011,236	3/8/1977	Grier				
			-					
	<del> </del>							
	<del>                                     </del>							
-								

		FOREIGN PA	TENT DOCU	MENTS		
Examiner Initials*		Foreign Patent Document	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	) Т <sup>6</sup>
	Cite No.	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )		Name of Patentee or Applicant of Cited Document		
<u> </u>	A03	WIPO 00/27819	5/18/2000	Schering Aktiengesellschaft		
	A04	WIPO 02/44156 A2	6/6/2002	Glaxo Group Limited		
	A05	WIPO 03/030902 A1	4/17/03	Tularik Inc.		
	A06	WIPO 01/21160 A2	3/29/2001	Axxima Pharmaceuticals		
	A07	WIPO 02/46171 A2	6/13/2002	Signal Pharmaceuticals Inc.		
	A08	WIPO 2004/001059 A2	12/31/2003	Bristol-Myers Squibb Co.		
	A09	WIPO 2004/014369 A1	2/19/2004	Aventis Pharma Deutschland GmbH		

Examiner	Date Considered	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional) . <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



(use as many sheets as necessary)

of

Sheet

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.